Key result
Procedural anticoagulation remains essential to balance ischemia and bleeding risks during PCI for MI.
Why the study?
Optimizing procedural anticoagulation regimens during PCI for STEMI and NSTEMI is essential to balance ischemic and bleeding risks and improve outcomes.
A review of procedural anticoagulation strategies during PCI for myocardial infarction to optimize the balance between ischemic and bleeding risks.
May inform anticoagulation choices in MI PCI; leaves open need for RCTs to optimize ischemic-bleeding balance.
The prognosis for patients with ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) is improved with the use of percutaneous coronary intervention (PCI). Choosing the best procedural anticoagulation regimen to balance the risks of ischemia and bleeding during PCI is essential to optimize outcomes. Heparin, a nonspecific indirect thrombin inhibitor, was the only anticoagulant agent used during PCI for several decades, first with aspirin alone and then with aspirin plus a platelet P2Y12 receptor inhibitor (ticlopidine or clopidogrel). Adding a platelet glycoprotein IIb/IIIa receptor inhibitor to heparin therapy further reduced the risk of stent thrombosis, reinfarction, and death among patients . . .
No takes yet. Share an insight, caveat, or question.
Gregg W. Stone (2017) conducted a review in Myocardial Infarction (STEMI and NSTEMI). Procedural anticoagulation was evaluated. Procedural anticoagulation regimens, such as heparin and glycoprotein IIb/IIIa inhibitors, are essential to balance ischemia and bleeding risks during PCI for myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: